EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of CYP2D6 Genotype and Inhibitor Use on Risperidone Metabolism in Children: Functional Insights Into the *17 and *29 Alleles

Matthew H Bennett iD, Ethan A Poweleit iD, Samuel E Vaughn iD, Brandon Retke iD, Paul Toren, Jeffrey R Strawn iD, Laura B Ramsey iD

Clinical and Translational Science · 2026-03 · 19 (3)

DOI: 10.1111/cts.70525 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 17.03.2026. Verfasst von Matthew H Bennett und 6 weiteren Autor:innen. Beteiligte Einrichtung: Kansas City University, Kansas City, Missouri, USA. Hauptthemen laut MEDLINE: Antipsychotic Agents, Cytochrome P-450 CYP2D6, Cytochrome P-450 CYP2D6 Inhibitors, Mental Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Risperidone, an atypical antipsychotic, is increasingly prescribed in pediatric patients with psychiatric disorders. It is primarily metabolized by CYP2D6 to 9‐hydroxyrisperidone, an active metabolite associated with a higher risk of adverse effects. The CYP2D6 * 17 and * 29 alleles are prevalent in individuals of African ancestry and less studied than variants found in European ancestry individuals. This knowledge gap contributes to differences in health outcomes in individuals of non‐European origin. The primary objective of this study is to replicate recently identified risperidone‐specific activity for the CYP2D6 * 17 and * 29 alleles. During psychiatric hospitalization, CYP2D6 was genotyped as part of routine care. Remnant plasma specimens were analyzed for risperidone and 9‐hydroxyrisperidone by tandem liquid chromatography mass spectrometry in 161 patients administered risperidone. The log‐transformed metabolite‐to‐parent ratio was used to estimate CYP2D6 enzymatic activity. The effect of each CYP2D6 allele on activity was assessed with linear regression that included strong CYP2D6 inhibitor use. Patients were predominantly white, non‐Hispanic youth, ages 5–18 years old (mean 12.5 years), and 26.7% were prescribed concomitant CYP2D6 inhibitors. The frequency of *17 and *29 alleles were 15.5% and 8.3%, respectively, among Black patients ( n = 42). After accounting for CYP2D6 inhibitors in the model, the activity of the * 17 allele was > 4‐fold that of the * 1 allele ( p = 0.006) and the * 29 allele was 10% that of the * 1 allele ( p = 0.021), comparable to alleles with no function. The * 17 allele confers greater metabolic activity for risperidone than reflected in current pharmacogenetic guidelines. Using existing activity scores may underestimate metabolism in * 17 carriers and overestimate it in * 29 carriers. Incorporating substrate‐specific activity scores and dosing recommendations would support improved dosing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsCytochrome P-450 CYP2D6Cytochrome P-450 CYP2D6 InhibitorsMental DisordersRisperidoneAdolescentChildChild, PreschoolFemaleHumansMaleAllelesGenotypePaliperidone PalmitatePharmacogenomic VariantsWhite

Stichwörter der Autor:innen

CYPmental healthpharmacogeneticspsychiatric

Substanzen

Antipsychotic AgentsCytochrome P-450 CYP2D6Cytochrome P-450 CYP2D6 InhibitorsPaliperidone PalmitateRisperidone

Autor:innen und Institutionen

  • Kansas City University, Kansas City, Missouri, USA.
  • Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, Missouri, USA.
  • Division of Child & Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Mass Spectrometry & Bioanalysis Core, Children's Mercy Research Institute, Children's Mercy Kansas City, Kansas City, Missouri, USA.
  • Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA.

ORCID-Profile: Matthew H Bennett, Ethan A Poweleit, Samuel E Vaughn, Brandon Retke, Jeffrey R Strawn, Laura B Ramsey

Förderung

  • NCATS NIH HHS
  • NICHD NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • National Center for Advancing Translational Sciences

Zitieren

APA

Bennett, M. H., Poweleit, E. A., Vaughn, S. E., Retke, B., Toren, P., Strawn, J. R., & Ramsey, L. B. (2026). Impact of CYP2D6 Genotype and Inhibitor Use on Risperidone Metabolism in Children: Functional Insights Into the *17 and *29 Alleles. Clinical and Translational Science, 19(3). https://doi.org/10.1111/cts.70525

Vancouver

Bennett MH, Poweleit EA, Vaughn SE, Retke B, Toren P, Strawn JR, et al. Impact of CYP2D6 Genotype and Inhibitor Use on Risperidone Metabolism in Children: Functional Insights Into the *17 and *29 Alleles. Clinical and Translational Science. 2026;19(3). doi:10.1111/cts.70525

BibTeX
@article{Bennett2026,
  author = {Bennett, Matthew H and Poweleit, Ethan A and Vaughn, Samuel E and Retke, Brandon and Toren, Paul and Strawn, Jeffrey R and Ramsey, Laura B},
  title = {Impact of CYP2D6 Genotype and Inhibitor Use on Risperidone Metabolism in Children: Functional Insights Into the *17 and *29 Alleles},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {3},
  doi = {10.1111/cts.70525}
}
Kostenlos starten →